Skip to main content

Advertisement

Table 1 Demographic characteristics of 4752 patients

From: Trends of risk classification and primary therapy for Japanese patients with prostate cancer in Nara Uro-Oncological Research Group (NUORG)–a comparison between 2004-2006 and 2007-2009

  Overall 2004-06 2007-09 Pvalue
  n = 4752 (%) n = 2303 (%) n = 2449 (%)  
Age (year)
Younger than 60 278 (5.9) 154 (6.7) 124 (5.1)  
60-69 1423 (29.9) 68.4 (29.7) 739 (30.2)  
70-79 2367 (49.8) 1117 (48.5) 1250 (51.0)  
80 or older 684 (14.4) 348 (15.1) 336 (13.7) 0.036
PSA at diagnosis
10.0 or less 2123 (44.7) 963 (41.8) 1160 (47.4)  
10.1-20 1117 (23.5) 554 (24.1) 563 (23.0) <0.001
Greater than 20 1512 (31.8) 786 (34.1) 726 (29.6)  
Gleason score
2-6 1771 (37.3) 906 (39.3) 865 (35.3)  
7 1614 (34.0) 722 (31.4) 892 (36.4)  
8-10 1367 (28.8) 675 (29.3) 692 (28.3) 0.001
Clinical T stage
T1 1605 (33.8) 766 (33.3) 839 (34.3)  
T2 1919 (40.4) 933 (40.5) 986 (40.3)  
T3 978 (20.6) 489 (21.2) 489 (20.0)  
T4 250 (5.3) 115 (5.0) 135 (5.5) 0.593
Clinical N stage
N0 4439 (93.4) 2161 (93.8) 2278 (93.0)  
N1 313 (6.6) 142 (6.2) 171 (7.0) 0.141
Clinical M stage
M0 4226 (88.9) 2019 (87.7) 2207 (90.1)  
M1a 17 (0.4) 11 (0.5) 6 (0.2)  
M1b 468 (9.8) 257 (11.2) 211 (8.6)  
M1c 41 (0.9) 16 (0.7) 25 (1.0) 0.008
Risk classification
Low 988 (20.8) 474 (20.6) 514 (21.0)  
Intermediate 1252 (26.3) 561 (24.4) 691 (28.2)  
High 1232 (25.9) 626 (27.2) 606 (24.7)  
Very high 657 (13.8) 319 (13.9) 338 (13.8)  
Metastatic 623 (13.1) 323 (14.0) 300 (12.3) <0.001